Electrolyte Blood Press.  2017 Dec;15(2):37-41. 10.5049/EBP.2017.15.2.37.

Edematous Hyponatremia Treated with Tolvaptan in a Patient with Amyotrophic Lateral Sclerosis

• Kim GH

• KMID: 2401151
• DOI: http://doi.org/10.5049/EBP.2017.15.2.37

Abstract

Amyotrophic lateral sclerosis (ALS) patients rarely present with either syndrome of inappropriate antidiuretic hormone secretion or generalized edema. Tolvaptan is a selective vasopressin V2 receptor antagonist that produces effective aquaresis, and its use in ALS patients has not been previously reported. A 50-year-old male ALS patient was admitted because of both generalized edema and dilutional hyponatremia. These manifestations were refractory to conventional diuretics and fluid therapy, but a very brisk diuresis was induced by tolvaptan administration. Edema and hyponatremia were also improved, and the patient was able to be discharged without tolvaptan. In this case report, we postulate how edema and dilutional hyponatremia developed in the patient, and discuss the mechanism of tolvaptan in treating hypervolemic hyponatremia. Further experience is necessary to evaluate the usefulness of tolvaptan in patients with neurological disorders.

Keyword

Amyotrophic lateral sclerosis; Diuresis; Edema; Hyponatremia; Tolvaptan

MeSH Terms

Amyotrophic Lateral Sclerosis*
Diuresis
Diuretics
Edema
Fluid Therapy
Humans
Hyponatremia*
Male
Middle Aged
Nervous System Diseases
Receptors, Vasopressin
Diuretics
Receptors, Vasopressin

Figure

• 

  Fig. 1 Chest X-ray findings. Partial atelectasis in the lower lobes of both lungs is shown.

• 

  Fig. 2 Clinical course during the admission. Changes in serum sodium concentration and daily urine volume in response to intravenous fluids, diuretics, and tolvaptan are presented.

Reference

1. Miller RG, Jackson CE, Kasarskis EJ, England JD, Forshew D, Johnston W, Kalra S, Katz JS, Mitsumoto H, Rosenfeld J, Shoesmith C, Strong MJ, Woolley SC. Quality Standards Subcommittee of the American Academy of Neurology. Practice parameter update: the care of the patient with amyotrophic lateral sclerosis: multidisciplinary care, symptom management, and cognitive/behavioral impairment (an evidence-based review): report of the Quality Standards Subcommittee of the American Academy of Neurology. Neurology. 2009; 73:1227–1233.

2. Jackson CE, McVey AL, Rudnicki S, Dimachkie MM, Barohn RJ. Symptom Management and End-of-Life Care in Amyotrophic Lateral Sclerosis. Neurol Clin. 2015; 33:889–908.

3. Oey PL, Vos PE, Wieneke GH, Wokke JH, Blankestijn PJ, Karemaker JM. Subtle involvement of the sympathetic nervous system in amyotrophic lateral sclerosis. Muscle Nerve. 2002; 25:402–408.

4. Inoue Y, Murakami T, Nakamura T, Morita K, Kaneda D, Nishino I, Hayashi T, Shinoto Y, Hatoko T, Kato T, Yonemitsu S, Muro S, Oki S. Syndrome of inappropriate antidiuretic hormone secretion associated with amyotrophic lateral sclerosis in a patient developing carbon dioxide narcosis. Intern Med. 2017; 56:797–803.

5. Yoshida Y, Kato B, Mizushima Y, Arai N, Matsui S, Maruyama M, Kobayashi M. Syndrome of inappropriate secretion of antidiuretic hormone associated with amyotrophic lateral sclerosis in respiratory failure. Respirology. 1999; 4:185–187.

6. Park ES, Huh YS, Kim GH. Is tolvaptan indicated for refractory oedema in nephrotic syndrome? Nephrology (Carlton). 2015; 20:103–106.

7. Boer PA, Morelli JM, Figueiredo JF, Gontijo JA. Early altered renal sodium handling determined by lithium clearance in spontaneously hypertensive rats (SHR): role of renal nerves. Life Sci. 2005; 76:1805–1815.

8. Rosenow EC 3rd, Segar WE, Zehr JE. Inappropriate antidiuretic hormone secretion in pneumonia. Mayo Clin Proc. 1972; 47:169–174.

9. Sladen A, Laver MB, Pontoppidan H. Pulmonary complications and water retention in prolonged mechanical ventilation. N Engl J Med. 1968; 279:448–453.

10. Tanaka A, Nakamura T, Sato E, Ueda Y, Node K. Different effects of tolvaptan in patients with idiopathic membranous nephropathy with nephrotic syndrome. Intern Med. 2017; 56:191–196.

11. Ecelbarger CA, Kim GH, Terris J, Masilamani S, Mitchell C, Reyes I, Verbalis JG, Knepper MA. Vasopressin-mediated regulation of epithelial sodium channel abundance in rat kidney. Am J Physiol Renal Physiol. 2000; 279:F46–F53.

12. Perucca J, Bichet DG, Bardoux P, Bouby N, Bankir L. Sodium excretion in response to vasopressin and selective vasopressin receptor antagonists. J Am Soc Nephrol. 2008; 19:1721–1731.

13. Miranda CA, Lee JW, Chou CL, Knepper MA. Tolvaptan as a tool in renal physiology. Am J Physiol Renal Physiol. 2014; 306:F359–F366.

14. Jujo K, Saito K, Ishida I, Furuki Y, Kim A, Suzuki Y, Sekiguchi H, Yamaguchi J, Ogawa H, Hagiwara N. Randomized pilot trial comparing tolvaptan with furosemide on renal and neurohumoral effects in acute heart failure. ESC Heart Fail. 2016; 3:177–188.